# Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

> **NCT03419130** · PHASE2 · WITHDRAWN · sponsor: **University of California, San Francisco**

## Conditions studied

- Infiltrating Bladder Urothelial Carcinoma
- Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage III Bladder Urothelial Carcinoma AJCC v6 and v7

## Interventions

- **RADIATION:** Hypofractionated Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03419130
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-07-18
- **Primary completion:** 2020-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn prior to patient enrollment
- **Last updated:** 2018-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03419130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03419130, "Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03419130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*